(2 weeks, 4 days ago)
Commons ChamberThe hon. Gentleman makes a good point. NICE is there for a particular reason: to ensure that the drugs being developed are available on the NHS when they meet the required threshold. Of course, we want to ensure that as new treatments become available, they are available for British patients. The work that is being done with Moderna and other pharmaceutical companies will ensure that British patients have access to some of the latest treatments as they come through the pipeline.
One of my earliest memories is being in a hospital room as my grandfather was dying of cancer. Ten days ago, I was in the same hospital as my father died with the same cancer—50 years in between, almost to the week, but no significant change in prognosis. Can the Minister assure me that what are termed the less survivable cancers, which are not necessarily rare cancers, are included as part of this work?
My heart goes out to my hon. Friend. I lost both my parents to cancer, and it does not matter when it happens in your life; it is just heartbreaking. As the children of those parents, you never get over it. Of course, we will have a concerted effort on less survivable cancers. In part, they are less survivable because the research has not been done, or not to the extent that we can develop better treatments for them. That is where we really have to shift the dial in the next decade. We have to make sure that people who have a cancer diagnosis have the best opportunities to live a long and fulfilling life after cancer.